Trombosis del stent en la era moderna: incidencia, consecuencias y factores predictores

Balaguer-Malfagón, José R.; Pomar-Domingo, Francisco; Vilar-Herrero, Juan V.; Viejo, Ana M. Planas-del; Pérez-Fernández, Emilio

doi:10.1157/13091890

Cited by 16 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ST is a severe complication that is associated with a high incidence of acute MI (22%–90%) and death (30%–45%) 79–81. The current procedure of DAT with aspirin and thienopyridine (usually clopidogrel) has reduced the incidence of ST to around 2% in the long term 82,83.…”

Section: Bleeding and Thrombotic Risk Stratification In The Perioperamentioning

confidence: 99%

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Llau

Ferrandis²,

Sierra³

et al. 2010

VHRM

View full text Add to dashboard Cite

The management of patients scheduled for surgery with a coronary stent, and receiving 1 or more antiplatelet drugs, has many controversies. The premature discontinuation of antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, and cardiac death, and surgery under an altered platelet function could also lead to an increased risk of bleeding in the perioperative period. Because of the conflict in the recommendations, this article reviews the current antiplatelet protocols after positioning a coronary stent, the evidence of increased risk of ST associated with the withdrawal of antiplatelet drugs and increased bleeding risk associated with its maintenance, the different perioperative antiplatelet protocols when patients are scheduled for surgery or need an urgent operation, and the therapeutic options if excessive bleeding occurs.

show abstract

Section: Bleeding and Thrombotic Risk Stratification In The Perioperamentioning

confidence: 99%

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Llau

Ferrandis²,

Sierra³

et al. 2010

VHRM

View full text Add to dashboard Cite

show abstract

“…When patients with ACS leave hospital and return to the community, however, a more significant problem becomes apparent due to the premature discontinuation of guideline-based therapies by patients and/or clinicians [1-3]. Furthermore, the majority of the morbidity and mortality that occurs in the early post-discharge period can be attributed to a failure to appropriately use these existing medications [5-8]. For example, premature medication discontinuation, when measured at one month post-discharge in a myocardial infarction population, decreased 12-month survival by 8% [2].…”

Section: Introductionmentioning

confidence: 99%

Home medicines reviews following acute coronary syndrome: study protocol for a randomized controlled trial

Bernal

Stafford

Bereznicki

et al. 2012

Trials

View full text Add to dashboard Cite

Background Despite continual improvements in the management of acute coronary syndromes, adherence to guideline-based medications remains suboptimal. We aim to improve adherence with guideline-based therapy following acute coronary syndrome using an existing service that is provided by specifically trained pharmacists, called a Home Medicines Review. We have made two minor adjustments to target the focus of the existing service including an acute coronary syndrome specific referral letter and a training package for the pharmacists providing the service. Methods/Design We will be conducting a randomized controlled trial to compare the directed home medicines review service to usual care following acute coronary syndromes. All patients aged 18 to 80 years and with a working diagnosis of acute coronary syndrome, who are admitted to two public, acute care hospitals, will be screened for enrolment into the trial. Exclusion criteria will include: not being discharged home, documented cognitive decline, non-Medicare eligibility, and presence of a terminal malignancy. Randomization concealment and sequence generation will occur through a centrally-monitored computer program. Patients randomized to the control group will receive usual post-discharge care. Patients randomized to receive the intervention will be offered usual post-discharge care and a directed home medicines review at two months post-discharge. The study endpoints will be six and twelve months post-discharge. The primary outcome will be the proportion of patients who are adherent to a complete, guideline-based medication regimen. Secondary outcomes will include hospital readmission rates, length of hospital stays, changes in quality of life, smoking cessation rates, cardiac rehabilitation completion rates, and mortality. Discussion As the trial is closely based on an existing service, any improvements observed should be highly translatable into regular practice. Possible limitations to the success of the trial intervention include general practitioner approval of the intervention, general practitioner acceptance of pharmacists' recommendations, and pharmacists' ability to make appropriate recommendations. A detailed monitoring process will detect any barriers to the success of the trial. Given that poor medication persistence following acute coronary syndrome is a worldwide problem, the findings of our study may have international implications for the care of this patient group. Trial registration Australian New Zealand Clinical Trials Registry ACTRN12611000452998

show abstract

Incidence, predictors, and clinical outcomes of early stent thrombosis in acute myocardial infarction patients treated with primary percutaneous coronary angioplasty (insights from the University of Ottawa Heart Institute STEMI registry)

Singh

Rashid

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Trombosis del stent en la era moderna: incidencia, consecuencias y factores predictores

Cited by 16 publications

References 10 publications

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Home medicines reviews following acute coronary syndrome: study protocol for a randomized controlled trial

Incidence, predictors, and clinical outcomes of early stent thrombosis in acute myocardial infarction patients treated with primary percutaneous coronary angioplasty (insights from the University of Ottawa Heart Institute STEMI registry)

Contact Info

Product

Resources

About